MYLAN PHARMACEUTICALS v. RESEARCH CORPORATION TECHNOLOGIES, Appeal No. 2017-2088 (Fed. Cir. February 1, 2019). Before Lourie, Bryson, and Wallach. Appealed from Patent Trial and Appeal Board. (IPR Joinder/Obviousness)
Research Corporation Technologies (RCT) owns a patent directed to compounds and compositions for treating central nervous system disorders. Argentum petitioned for an inter partes review of this patent, and the PTAB instituted an IPR on grounds of obviousness.
After institution, Mylan, Breckenridge, and Alembic filed petitions for IPR review and motions for joinder. These petitioners had been sued for infringement of the same patent more than a year previously. The PTAB instituted the additional reviews and joined each with the Argentum IPR.
Before the PTAB, Argentum asserted that one skilled in the art would have been motivated to replace an -NH- group in an alkoxyamine group in a compound disclosed in a primary reference with a -CH2– group. Argentum relied on a drug discovery book chapter for teaching that the -NH- and -CH2– groups have chemical or physical similarities, and produce broadly similar biological properties.
The PTAB found that a person skilled in the art would not have been motivated to modify the prior art compound as alleged by Argentum. The PTAB found that: (1) the primary reference taught compounds without the -NH- group had reduced activity, and (2) Argentum’s proposed modification would have led to a compound with significantly different biological activity. In summary, the PTAB found that the challenged claims were not unpatentable.
Three of the joined petitioners (Mylan, Breckenridge, and Alembic) appealed. RCT challenged whether these petitioners have standing to challenge the PTAB’s decision.
(1) Do the appellants, who were joined as petitioners more than one year after being sued, have standing to appeal?
(2) Did the PTAB err in determining there was no motivation to modify the prior art compound? (continue reading)
Summary by: Paige Soon
To view additional Federal Circuit decisions, please visit our Federal Circuit Case Summaries page.